The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
The collaboration highlights the rising importance of intranasal delivery in developing non-vaccine approaches to respiratory disease prevention
Pfizer recommends that shareholders do not tender their shares in response to Tutanota’s offer
The conflict is also triggering a widening public health emergency
The program provides pharmaceutical manufacturers with auditable, primary emissions data and verified proof of a 30% CO? reduction across DFE Pharma’s lactose portfolio
Lupin’s double ‘A’ rating in Climate and Water exemplifies its steadfast commitment to sustainability
CuraTeQ Biologics and BioFactura USA to terminate agreement mutually
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
The company had achieved the highest "A" rating in Climate Change
Subscribe To Our Newsletter & Stay Updated
